[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657186":3},{"organization":4,"outcomesModule":7,"designInfo":53,"detailedDescription":56,"studyPopulation":56,"armGroups":60,"interventions":66,"overallOfficials":56,"centralContacts":72,"locations":78,"responsibleParty":105,"collaborators":56,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":56,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":56,"enrollmentInfo":116,"targetDuration":56,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":56,"overallStatus":126,"whyStopped":56,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":49},[9,13],{"measure":10,"description":11,"timeFrame":12},"The incidence and case number of DLT (Dose Limiting Toxicity) during observation period","DLT is short for Dose Limiting Toxicity, dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.","Up to 21 days following first dose",{"measure":14,"description":15,"timeFrame":16},"Number of participants with adverse events and serious adverse events as assessed by CTCAE v6.0","AE refers to any untoward medical occurrence or deterioration of existing medical event after the investigational treatment, whether or not considered related to the study treatment.","Up to 30 days following last dose",[18,22,25,28,31,33,37,40,43,46],{"measure":19,"description":20,"timeFrame":21},"Characterization of the PK profile of ASKC189","AUC(inf) after single dose and AUC (0-τ) after single and multiple doses Maximum blood concentration (Cmax)","At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose",{"measure":23,"description":24,"timeFrame":21},"Characterization of the PK profile of ASKC189: blood concentration characteristics","Time to maximum blood concentration (Tmax)",{"measure":26,"description":27,"timeFrame":21},"Characterization of the PK profile of ASKC189: steady state characterization","Accumulation ratio (AR) at steady-state",{"measure":29,"description":30,"timeFrame":21},"Characterization of the PK profile of ASKC189: drug level characterization in blood","Apparent clearance (CL\u002FF) after single and multiple doses",{"measure":19,"description":32,"timeFrame":21},"ASKC189 apparent terminal half-life (t1\u002F2)",{"measure":34,"description":35,"timeFrame":36},"Objective response rate (ORR)","ORR is defined as the proportion of subjects with confirmed CR or confirmed PR (based on RECIST Version 1.1).","Up to approximately 3 years",{"measure":38,"description":39,"timeFrame":36},"Disease control rate (DCR)","DCR is defined as the proportion of subjects with CR, PR, or SD (based on RECIST Version 1.1).",{"measure":41,"description":42,"timeFrame":36},"Duration of Response (DoR)","DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first.",{"measure":44,"description":45,"timeFrame":36},"Progression-free survival (PFS)","PFS is defined as the time from the start of treatment until the first documentation of disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first.",{"measure":47,"description":48,"timeFrame":36},"Overall survival (OS)","OS defined as the time from the first dose to death from any cause.",[50],{"measure":51,"description":52,"timeFrame":36},"The identification of potential predictive biomarkers associated with response or resistance to ASKC189","Correlation of clinical outcomes with biomarkers to specific RAS mutation subtypes, and co-mutations in tumor tissue at baseline and progressive disease.",{"allocation":54,"interventionModel":55,"interventionModelDescription":56,"primaryPurpose":57,"observationalModel":56,"timePerspective":56,"maskingInfo":58},"NA","SINGLE_GROUP",null,"TREATMENT",{"masking":59,"maskingDescription":56,"whoMasked":56},"NONE",[61],{"label":62,"type":63,"description":56,"interventionNames":64},"ASKC189 oral capsule","EXPERIMENTAL",[65],"Drug: ASKC189",[67],{"type":68,"name":69,"description":70,"armGroupLabels":71,"otherNames":56},"DRUG","ASKC189","ASKC189 for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.",[62],[73],{"name":74,"role":75,"phone":76,"phoneExt":56,"email":77},"Jiangsu Aosaikang Study Director","CONTACT","+86 025 52169999","ctr-contact@ask-pharm.com",[79,94],{"facility":80,"status":56,"city":81,"state":56,"zip":56,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"Peking University Cancer Hospital","Beijing","China","CN",{"type":85,"coordinates":86},"Point",[87,88],116.39723,39.9075,{"lat":88,"lon":87},[91],{"name":92,"role":93,"phone":56,"phoneExt":56,"email":56},"Lin Shen, MD","PRINCIPAL_INVESTIGATOR",{"facility":95,"status":56,"city":96,"state":56,"zip":56,"country":82,"countryCode":83,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Shanghai East Hospital","Shanghai",{"type":85,"coordinates":98},[99,100],121.45806,31.22222,{"lat":100,"lon":99},[103],{"name":104,"role":93,"phone":56,"phoneExt":56,"email":56},"Caicun Zhou, MD",{"type":106,"investigatorFullName":56,"investigatorTitle":56,"investigatorAffiliation":56,"oldNameTitle":56,"oldOrganization":56},"SPONSOR","100657186","phase-1-evaluation-of-ras-inhibitor-treatment-in-participants-with-advanced-or-metastatic-solid-tumors-harboring-ras-mutations-100657186",false,"NCT07836036","Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations","A Phase I, Multi-center, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ASKC189 in Chinese Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors Carrying RAS Gene Mutations.","Inclusion Criteria:\n\n1. Aged ≥18 years old at the time of informed consent\n2. Able to provide informed consent voluntarily before any study-related activities and according to local guidelines\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n4. Have an estimated life expectancy ≥ 12 weeks\n5. Have histological or cytological evidence of a diagnosis of cancer that is advanced and\u002For metastatic with progression after treatment with available standard therapies.\n6. Documentation of KRAS\u002FNRAS\u002FHRAS mutation determined by validated local testing of tumor tissue or circulating free DNA (cfDNA) in a certified laboratory\n7. Have consented to provide archival tumor tissue collected within 3 years or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.\n8. Have adequate organ functions\n9. Have discontinued all previous treatments for cancer with resolution of any adverse events (AEs) to ≤ Grade 1\n\nExclusion Criteria:\n\n1. Are currently enrolled in a clinical study involving an investigational product or any other type of medical research\n2. Have tumors previously tested positive for Class I BRAF mutations i.e. V600X\n3. Prior treatment with a pan-RAS(ON) inhibitor\n4. Gastrointestinal conditions that may interfere with drug absorption\n5. Have a serious concomitant systemic disorder\n6. Have a serious pre-existing medical condition(s)\n7. Prior or second concurrent primary malignancies\n8. Moderate or severe cardiovascular disease\n9. Have symptomatic central nervous system (CNS) malignancy or metastasis","ALL","18 Years",{"count":117,"type":118},200,"ESTIMATED","INTERVENTIONAL",[121],"PHASE1","This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ASKC189 in in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations",[124,125],"Solid Tumor","RAS Mutation","NOT_YET_RECRUITING","2026-09-21",{"date":129,"type":130},"2026-09-23","ACTUAL",{"date":132,"type":118},"2026-09-30",{"date":134,"type":118},"2029-03-30",{"name":5,"class":6},2]